US president says he is pausing US effort to guide stranded vessels out of the strait of Hormuz but blockade remains Donald Trump has announced that he is pausing ‘Project Freedom’, the US effort to guide stranded vessels out of the strait of Hormuz, so that he can finalise a deal with Iran, but added that his blockade of Iranian ports would remain in place. Trump announced the decision in a socia...
US president says he is pausing US effort to guide stranded vessels out of the strait of Hormuz but blockade remains Donald Trump has announced that he is pausing ‘Project Freedom’, the US effort to guide stranded vessels out of the strait of Hormuz, so that he can finalise a deal with Iran, but added that his blockade of Iranian ports would remain in place. Trump announced the decision in a social media post, saying he was pausing the effort for a short period to give space for US efforts to finalise a settlement with Iran to end the war. Continue reading...
(RTTNews) - Australian shares are trading notably higher on Wednesday, reversing the losses in the previous two sessions, with the benchmark S&P/ASX 200 moving well above the 8,700 level, following the broadly positive cues from Wall Street overnight, with gains in mining and fin
(RTTNews) - Australian shares are trading notably higher on Wednesday, reversing the losses in the previous two sessions, with the benchmark S&P/ASX 200 moving well above the 8,700 level, following the broadly positive cues from Wall Street overnight, with gains in mining and fin
Texas Doctor Found Guilty For Illegally Distributing Millions Of Opioid Pills Authored by Kimberly Hayek via The Epoch Times (emphasis ours), A federal jury in Texas found a physician guilty of unlawfully distributing over a million pills of opioids and other controlled substances from a Houston-area clinic that operated as a pill mill, the Justice Department announced Monday. Tablets of opioid pa...
Texas Doctor Found Guilty For Illegally Distributing Millions Of Opioid Pills Authored by Kimberly Hayek via The Epoch Times (emphasis ours), A federal jury in Texas found a physician guilty of unlawfully distributing over a million pills of opioids and other controlled substances from a Houston-area clinic that operated as a pill mill, the Justice Department announced Monday. Tablets of opioid painkiller Oxycodone delivered on medical prescription in Washington on Sept. 18, 2019. Eric Baradat/AFP via Getty Images Dr. Barbara Marino, 65, of Tomball, was the sole prescribing physician at Angels Clinica, where she prescribed oxycodone, hydrocodone, and the muscle relaxer carisoprodol despite no legitimate medical purpose. The clinic accepted only cash and charged based on the prescriptions. “Medical physicians who exploit their prescribing authority for profit over patient care break an inherent trust with their patients and we will hold them accountable,” Assistant Attorney General Colin M. McDonald of the Justice Department’s National Fraud Enforcement Division said in a statement. “The Department of Justice remains committed to protecting the public from dangerous and unlawful distribution of controlled substances, especially when the drug dealer is a doctor.” DEA Assistant Administrator Cheri Oz said patients put their trust and lives into the hands of medical and health care professionals. “The highly addictive, dangerous misused drugs in this case—oxycodone and hydrocodone—are meant to treat pain, not cause it,” Oz said. “DEA remains relentless in our pursuit of those who poison our communities and exploit our health care system, all to line their own pockets with the profit from other’s pain.” Prosecutors noted that many patients were delivered by street-level “crew leaders” or “runners” who then filled the prescriptions and peddled the pills. Marino received over $400,000 in less than a year for writing the scripts, while ignoring red flags outlined in Texas p...
CDC Data Centres is forecasting a surge in earnings over the next three years after agreeing Australia’s largest data center contract, stoking the value of its largest holder Infratil Ltd. The company expects operating earnings to rise to at least A$1 billion ($721 million) in the 2027-28 financial year from nearly A$400 million in the current year, it said on a conference call Wednesday in Wellin...
CDC Data Centres is forecasting a surge in earnings over the next three years after agreeing Australia’s largest data center contract, stoking the value of its largest holder Infratil Ltd. The company expects operating earnings to rise to at least A$1 billion ($721 million) in the 2027-28 financial year from nearly A$400 million in the current year, it said on a conference call Wednesday in Wellington. Shares in New Zealand infrastructure investor Infratil, which owns 49.7% of CDC, surged 12% in Wellington, the most in more than five years. CDC Chief Executive Greg Boorer said the contract win is a “massive tick of approval for Australia as a global hub for intelligence generation.” “It reaffirms Australia as a very trusted geography in a world that is getting increasingly geopolitically imbalanced,” he said. The contract, announced late Tuesday, is for 555 megawatts of new capacity and doubles CDC’s contracted capacity to 1 gigawatt. The deal is with an unidentified US customer and has a minimum term of 10 years. No financial details were provided with CDC saying it would be debt funded and requires no new equity from Infratil or other holders, which include Australia’s Future Fund and the Commonwealth Superannuation Corp. The capacity will be delivered over two years through 2029 on sites already under development. When fully deployed, the 1 gigawatt of contracted capacity would deliver annualized contracted operating earnings of about A$2 billion, the company said. CDC expects its capital spending in 2027-28 will be A$3.8 billion to A$4.2 billion, it said.
Earnings Call Insights: Logitech (LOGI) Q4 FY2026 Management View "Fiscal year '26 proved what our model is capable of in any environment, successful innovation, best-in-class execution and real earnings expansion," said CEO & Director Johanna Faber. "We captured significant new market share in key segments and geographies" and delivered "6% net sales growth in U.S. dollars and 4% in constant curr...
Earnings Call Insights: Logitech (LOGI) Q4 FY2026 Management View "Fiscal year '26 proved what our model is capable of in any environment, successful innovation, best-in-class execution and real earnings expansion," said CEO & Director Johanna Faber. "We captured significant new market share in key segments and geographies" and delivered "6% net sales growth in U.S. dollars and 4% in constant currency," alongside "non-GAAP gross margins of 43.6%" and "an operating margin of 18.8%." "In Q4, we again drove significant global market share growth with a 140 basis point increase in personal workspace," Faber said, adding: "We accelerated global gaming to high single-digit growth" and "delivered superb margins and a 25% increase in non-GAAP operating income versus last year." "With structurally strong gross margins and a pristine balance sheet, we'll invest in the business to accelerate future growth," Faber said, outlining three focus areas: "R&D and product innovation" (including "new Rally AI video conferencing cameras, which are shipping this summer"), "Logitech for Business" (prioritizing "education, government and health care"), and "building an iconic brand" using "proven high ROAS marketing." "The team delivered a very strong close to the year, characterized by solid demand, exceptional profitability and cash generation," said CFO Matteo Anversa. "Net sales were $1.086 billion" in Q4, and "our non-GAAP gross margin rate was exceptionally strong at 44.8%." Outlook "Net sales" in Q1 FY2027 are expected "to grow 2% to 4% in constant currency," Anversa said, and "this amount includes approximately 150 basis points of negative impact from the Middle East conflict." "Non-GAAP operating income is expected to be between $195 million and $215 million." "Making statements right now beyond the first quarter due to the visibility of -- in the current world conditions that we live in... it's a bit premature," Anversa said, while adding that OpEx would remain within "24% to 26%...
Earnings Call Insights: InnovAge Holding Corp. (INNV) Q3 fiscal 2026 Management view "We delivered a solid third quarter and continue to see steady momentum across the business." (Chief Executive Officer Patrick Blair) "For the quarter, we reported approximately $252 million in total revenue, center-level contribution margin of $61 million and adjusted EBITDA of $30 million." (CEO Blair) "Based on...
Earnings Call Insights: InnovAge Holding Corp. (INNV) Q3 fiscal 2026 Management view "We delivered a solid third quarter and continue to see steady momentum across the business." (Chief Executive Officer Patrick Blair) "For the quarter, we reported approximately $252 million in total revenue, center-level contribution margin of $61 million and adjusted EBITDA of $30 million." (CEO Blair) "Based on our year-to-date operating trends and financial performance, we are once again raising our fiscal year 2026 guidance for revenue and adjusted EBITDA." (CEO Blair) "We now expect revenue in the range of $950 million to $975 million and adjusted EBITDA in the range of $85 million to $90 million." (CEO Blair) "We ended the quarter serving approximately 8,050 participants in 6 states across 20 centers." (CEO Blair) "That includes continued investment in our clinical teams and interdisciplinary model, advancing our technology platform, including early and closely monitored applications of AI to improve care coordination and participant experience" and "strengthening how we measure and manage quality." (CEO Blair) "These may include acquisitions, joint ventures, partnerships or participation in new programs and demonstration models that align with our capabilities." (CEO Blair) "We expect Medicare rates to increase approximately 1.5% to 2% in fiscal year 2027" and "we are also being thoughtful about our assumptions as we look ahead to fiscal 2027." (CEO Blair) "Corporate general and administrative expenses of $76.5 million increased 98.3% compared to the third quarter of fiscal year 2025, primarily driven by an increase in litigation liability." (Chief Financial Officer Benjamin Adams) Outlook "We now expect revenue in the range of $950 million to $975 million and adjusted EBITDA in the range of $85 million to $90 million." (CEO Blair) "We expect our ending census for fiscal year 2026 to be between 7,900 and 8,100 participants and member months to be in the range of 92,900 to 95...
Earnings Call Insights: DaVita (DVA) Q1 2026 Management View "We delivered strong financial results ahead of our expectations with outperformance from each element of our U.S. dialysis trilogy; treatment volume, revenue per treatment and cost per treatment." (CEO & Executive Director Javier Rodriguez) "As a result, we're raising our volume growth expectations for the full year from flat to a range...
Earnings Call Insights: DaVita (DVA) Q1 2026 Management View "We delivered strong financial results ahead of our expectations with outperformance from each element of our U.S. dialysis trilogy; treatment volume, revenue per treatment and cost per treatment." (CEO & Executive Director Javier Rodriguez) "As a result, we're raising our volume growth expectations for the full year from flat to a range of 25 to 50 basis point increase." (CEO & Executive Director Rodriguez) "We're taking a disciplined approach to AI that we've been building towards for years" and highlighted "ScheduleHub" as "a new tool that dynamically processes changes in each center's patient census, capacity and teammate availability to recommend optimal patient and staffing schedules in real time." (CEO & Executive Director Rodriguez) "ACA open enrollment is trending towards a slightly favorable outcome relative to our prior expectations of an approximately $40 million headwind in 2026" while warning that "more patients selecting lower-level bronze plans" could mean "a modest RPT headwind." (CEO & Executive Director Rodriguez) "First quarter adjusted operating income was $482 million, adjusted earnings per share from continuing operations was $2.87 and free cash flow was $140 million." (CFO & Treasurer Joel Ackerman) Outlook "We're raising and narrowing our guidance for adjusted operating income to a range of $2.15 billion to $2.25 billion" and "raising our adjusted EPS guidance to a range of $14.10 to $15.20 per share." (CEO & Executive Director Rodriguez) "The increased guidance is primarily the result of our higher volume forecast for the year and lower patient care costs." (CEO & Executive Director Rodriguez) "We still expect full year RPT growth in the range of 1% to 2%." (CFO & Treasurer Ackerman) Compared with the prior quarter’s 2026 setup, management moved the full-year treatment volume assumption from "approximately flat to 2025" to "a range of 25 to 50 basis point increase" and said the la...
Earnings Call Insights: Advanced Micro Devices (AMD) Q1 2026 Management View "We delivered an outstanding start to the year driven by accelerating demand for AI infrastructure across our portfolio" (Chair, President & CEO Lisa Su), highlighting 57% year-over-year Data Center revenue growth and calling the quarter "a clear inflection in our growth trajectory and a structural shift in our business."...
Earnings Call Insights: Advanced Micro Devices (AMD) Q1 2026 Management View "We delivered an outstanding start to the year driven by accelerating demand for AI infrastructure across our portfolio" (Chair, President & CEO Lisa Su), highlighting 57% year-over-year Data Center revenue growth and calling the quarter "a clear inflection in our growth trajectory and a structural shift in our business." Su emphasized EPYC share momentum and platform breadth, saying, "Share gains accelerated year-over-year, reflecting the ramp of fifth-gen EPYC Turin CPUs" and adding that the company remains "on track to launch Venice later this year." On AI infrastructure partnerships, Su said AMD expanded its relationship with Meta "to deploy up to 6 gigawatts of AMD Instinct GPUs spanning several product generations," including "a custom GPU accelerator based on our MI450 architecture," with "shipments... on track to begin in the second half of the year." Su raised long-term CPU demand assumptions, stating, "we now expect the server CPU TAM to grow at greater than 35% annually, reaching over $120 billion by 2030," and added, "we now expect server CPU revenue to grow by more than 70% year-over-year in the second quarter." "First quarter revenue was $10.3 billion... growing 38% year-over-year" (Executive VP, CFO & Treasurer Jean Hu), who also reported non-GAAP gross margin of 55% and said "operating income was $2.5 billion, representing a 25% operating margin." Outlook "We expect revenue to be approximately $11.2 billion, plus or minus $300 million" for Q2 (Executive VP Hu), with non-GAAP gross margin "approximately 56%" and non-GAAP operating expenses "approximately $3.3 billion." Su said the company is increasing capacity with partners and added, "we are working closely with our supply chain partners to meaningfully increase our wafer and back-end capacities" to support stronger server CPU demand signals. Compared with the prior quarter’s Q1 outlook of "approximately $9.8 billion, plus ...
Lean hog futures posted 65 cent to $1.80 gains on Tuesday. USDA’s national base hog price was not reported on Tuesday afternoon due to packer submission issues. The CME Lean Hog Index was back down 27 cents on May 1 at $91.03. Monthly trade data from Census converted to a...
Lean hog futures posted 65 cent to $1.80 gains on Tuesday. USDA’s national base hog price was not reported on Tuesday afternoon due to packer submission issues. The CME Lean Hog Index was back down 27 cents on May 1 at $91.03. Monthly trade data from Census converted to a...